Active Ingredient History
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bariatric Surgery (Early Phase 1)
Blood Glucose (Phase 1/Phase 2)
Coronary Disease (Phase 4)
Critical Illness (Phase 2)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 1 (Early Phase 1)
Diabetes Mellitus, Type 2 (Phase 4)
Healthy Volunteers (Phase 2/Phase 3)
Heart Failure (Phase 1)
Hemorrhage (Phase 1/Phase 2)
Hyperglycemia (Phase 1)
Hypoglycemia (Phase 2)
Insulin Resistance (Early Phase 1)
Insulin Secretion (Phase 1)
Intestinal Failure (Phase 1/Phase 2)
Pancreatic Diseases (Phase 1)
Short Bowel Syndrome (Phase 1/Phase 2)
Urination Disorders (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue